Market capitalization | $10.50b |
Enterprise Value | $9.99b |
P/E (TTM) P/E ratio | 29.58 |
EV/FCF (TTM) EV/FCF | 18.66 |
EV/Sales (TTM) EV/Sales | 4.83 |
P/S ratio (TTM) P/S ratio | 5.07 |
P/B ratio (TTM) P/B ratio | 11.89 |
Revenue growth (TTM) Revenue growth | 16.24% |
Revenue (TTM) Revenue | $2.07b |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
11 Analysts have issued a Medpace forecast:
11 Analysts have issued a Medpace forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2,071 2,071 |
16%
16%
|
|
Gross Profit | 586 586 |
23%
23%
|
|
EBITDA | 438 438 |
20%
20%
|
EBIT (Operating Income) EBIT | 409 409 |
25%
25%
|
Net Profit | 366 366 |
34%
34%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH.
Head office | United States |
CEO | August Troendle |
Employees | 5,900 |
Founded | 1992 |
Website | www.medpace.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.